AUROVELA 24 FE
Clinical safety rating
cautionComprehensive clinical and safety monograph for AUROVELA 24 FE (AUROVELA 24 FE).
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
| Metabolism | Primarily metabolized via CYP3A4. Norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes phase I (hydroxylation via CYP3A4) and phase II (glucuronidation) metabolism. |
| Excretion | Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates. |
| Half-life | Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days. |
| Protein binding | Norethindrone: ~91% to albumin and SHBG; Ethinyl estradiol: ~97% to albumin. |
| Volume of Distribution | Norethindrone: ~1.5 L/kg; Ethinyl estradiol: ~15 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Norethindrone: ~64%; Ethinyl estradiol: ~43% (oral). |
| Onset of Action | Oral administration: contraceptive effect requires 7 days of continuous dosing. |
| Duration of Action | 24-hour dosing interval; missed pill increases ovulation risk. |
| Molecular Weight | 340.46 |
| Action Class | Oral Contraceptive; Estrogen/Progestin Combination |
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or acute renal failure due to potential accumulation of components. |
| Liver impairment | Contraindicated in patients with hepatic impairment or active liver disease. No specific dose adjustments provided for mild impairment; use not recommended in Child-Pugh class B or C. |
| Pediatric use | Safety and efficacy established in females of reproductive age post-menarche. Dosing same as adults (0.10 mg/1.0 mg daily for 24 days, then placebo for 4 days). |
| Geriatric use | Not indicated for use in postmenopausal women. No specific dose adjustments required for elderly, but consider risks of thromboembolism and other comorbidities. |
| 1st trimester | Not recommended for use during pregnancy. Data suggest increased risk of congenital anomalies, including cardiovascular and musculoskeletal defects, following exposure to progestins during the first trimester. |
| 2nd trimester | Use is contraindicated during pregnancy due to potential harm to the fetus. Norethindrone may cause androgenic effects, including ambiguous genitalia in female fetuses. |
| 3rd trimester | Use is contraindicated during pregnancy. Norethindrone may delay labor and cause fetal harm, including potential virilization of female fetuses. |
Clinical note
Comprehensive clinical and safety monograph for AUROVELA 24 FE (AUROVELA 24 FE).
| Placental transfer | Both components cross the placenta. Norethindrone exhibits significant placental transfer; ethinyl estradiol crosses at lower levels but is still detectable in fetal circulation. |
| Breastfeeding | Norethindrone and ethinyl estradiol are excreted in human milk in small amounts. Use is generally avoided during breastfeeding as it may reduce milk production and affect infant development. Alternative methods of contraception are preferred. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and potential for neonatal hepatic dysfunction. Contraindicated in pregnancy due to teratogenicity. |
| Fetal Monitoring | Regular prenatal visits; fetal ultrasound to rule out congenital anomalies if inadvertent exposure occurs; monitor maternal blood pressure, liver function, and symptoms of thrombosis. Contraception adherence must be ensured to avoid pregnancy. |
| Fertility Effects | May delay return of fertility after discontinuation due to anovulatory cycles. Long-term use is not associated with permanent infertility. Post-pill amenorrhea can occur but typically resolves within months. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular uterine bleeding, Mood changes |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebral hemorrhage |
Thromboembolic disordersBreast cancer (current or history)Hepatic adenoma or carcinomaUndiagnosed abnormal genital bleedingPregnancyJaundice with prior pill useActive liver disease
| Precautions | Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI), Hepatic neoplasia, Gallbladder disease, Hypertension, Hyperkalemia in renal impairment (due to drospirenone component in some formulations; not applicable to this product), Glucose intolerance, Depression, Uterine bleeding irregularities, Follicular atresia and amenorrhea after discontinuation, Contact lens intolerance |
| Food/Dietary | No food interactions documented. Grapefruit juice may increase estrogen exposure but not clinically significant; no restriction needed. |
| Clinical Pearls | AUROVELA 24 FE is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate placebo. The iron supplement in placebo pills is not bioavailable and does not treat iron deficiency. Counsel that withdrawal bleed typically occurs during the 4th week (iron pills). Missed pills algorithm: if one active pill missed, take as soon as remembered; if two or more missed, take last missed and use backup contraception for 7 days. Induction of CYP3A4 by rifampin, anticonvulsants, St. John's wort may reduce efficacy. Do not prescribe with concomitant hepatitis C therapy containing ombitasvir/paritaprevir/ritonavir due to ALT elevations. |
| Patient Advice | Take one tablet daily at the same time, preferably after the evening meal to reduce nausea. · The last 7 tablets are brown iron pills; you will have a withdrawal bleed during this time. · If you vomit within 4 hours of taking an active pill, take another active pill from a separate pack. · Missing two or more active pills may require backup contraception (condoms) for 7 days. · Smoking increases risk of serious cardiovascular side effects; avoid smoking while on this medication. · Report any symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes. · This medication does not protect against HIV or other sexually transmitted infections. · Store at room temperature away from moisture and heat. |
Loading safety data…